Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.07 +1.5%	$1.96	$1.60 ▼ $2.54	$798.36M	1.03	1.64 million shs	1.20 million shs
CTOR Citius Oncology	$4.64 -1.5%	$1.75	$0.55 ▼ $49.00	$331.99M	3.06	1.19 million shs	143,268 shs
PHAT Phathom Pharmaceuticals	$9.12 +5.3%	$6.34	$2.21 ▼ $19.71	$636.67M	0.45	1.95 million shs	421,464 shs
REPL Replimune Group	$9.34 -3.2%	$9.06	$6.44 ▼ $17.00	$720.02M	0.61	871,137 shs	869,585 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	0.00%	+6.81%	+3.03%	+25.93%	-8.52%
CTOR Citius Oncology	-11.47%	+8.28%	+348.53%	+588.60%	+470,999,900.00%
PHAT Phathom Pharmaceuticals	-1.20%	-9.70%	-2.91%	+103.76%	-15.92%
REPL Replimune Group	+2.12%	+3.88%	-7.03%	+35.15%	+18.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	2.0167 of 5 stars	0.0	5.0	0.0	1.4	0.0	2.5
CTOR Citius Oncology	0.3981 of 5 stars	1.0	0.0	0.0	3.0	1.7	0.0
PHAT Phathom Pharmaceuticals	3.4531 of 5 stars	4.5	1.0	0.0	0.6	5.0	0.6
REPL Replimune Group	4.1654 of 5 stars	3.6	1.0	4.5	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
CTOR Citius Oncology	2.00	Hold	$3.00	-35.34% Downside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	91.89% Upside
REPL Replimune Group	3.13	Buy	$20.83	123.05% Upside

Current Analyst Ratings Breakdown

Latest CTOR, PHAT, CRON, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.79	N/A	N/A	$2.90 per share	0.71
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
PHAT Phathom Pharmaceuticals	$55.25M	11.52	N/A	N/A	($3.71) per share	-2.46
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	15.92	69.00	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-53.88%	-18.86%	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)

Latest CTOR, PHAT, CRON, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
CTOR Citius Oncology	0.11	0.36	0.05
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
CTOR Citius Oncology	70.52%
PHAT Phathom Pharmaceuticals	99.01%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
CTOR Citius Oncology	4.57%
PHAT Phathom Pharmaceuticals	24.10%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	359.07 million	Optionable
CTOR Citius Oncology	N/A	71.55 million	68.28 million	N/A
PHAT Phathom Pharmaceuticals	110	69.81 million	52.99 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

CTOR, PHAT, CRON, and REPL Headlines

Recent News About These Companies

Replimune Group (NASDAQ:REPL) Shares Up 4.4% - Should You Buy?

July 7 at 2:25 PM | marketbeat.com

Moody Aldrich Partners LLC Makes New $1.93 Million Investment in Replimune Group, Inc. (NASDAQ:REPL)

July 4, 2025 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Replimune Group (NASDAQ:REPL)

July 4, 2025 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Earns "Buy" Rating from HC Wainwright

July 3, 2025 | marketbeat.com

Replimune Group, Inc. (REPL) - Yahoo Finance

July 1, 2025 | finance.yahoo.com

Replimune Group, Inc. (NASDAQ:REPL) Receives $20.83 Consensus Price Target from Analysts

June 28, 2025 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

June 25, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight Recommendation

June 20, 2025 | msn.com

Replimune Group (NASDAQ:REPL) Coverage Initiated at Cantor Fitzgerald

June 20, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE

June 14, 2025 | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.comQ

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings

May 24, 2025 | uk.investing.com

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings

May 24, 2025 | nasdaq.com

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript

May 23, 2025 | insidermonkey.com

Emily Luisa Hill Sells 2,535 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

May 23, 2025 | insidertrades.com

Q4 2025 Replimune Group Inc Earnings Call

May 22, 2025 | uk.finance.yahoo.com

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop
Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks
By Gabriel Osorio-Mazilli | June 9, 2025
View Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks
Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
By Thomas Hughes | June 30, 2025
View Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
Why Unity Software May Be the AI Breakout No One Saw Coming
By Gabriel Osorio-Mazilli | June 9, 2025
View Why Unity Software May Be the AI Breakout No One Saw Coming

CTOR, PHAT, CRON, and REPL Company Descriptions

Cronos Group NASDAQ:CRON

$2.07 +0.03 (+1.47%)

As of 02:58 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Citius Oncology NASDAQ:CTOR

$4.64 -0.07 (-1.49%)

As of 02:52 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.12 +0.46 (+5.31%)

As of 02:58 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Replimune Group NASDAQ:REPL

$9.34 -0.31 (-3.21%)

As of 02:57 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time